27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events.
- The treatment reduced healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits by approximately 62% among patients with one or more comorbidity and about 51% overall.
- For patients with one or more comorbidity, KB109 reduced the median time to resolving the 13 overall COVID-19 symptoms from 30 to 21 days.
- The study also demonstrated a significant reduction in recovery time for patients aged 45 and older or with one or more comorbidity who received KB109 plus self-supportive care compared to patients receiving self-supportive care alone.
- KB109 is a novel, orally administered product candidate based on the Company's Microbiome Metabolic Therapy platform.
- Price Action: KLDO shares are up 8.86% at $10.81 in premarket trading on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.